AstraZeneca

CRISPR gene editing
#AstraZeneca #Cancer Research Horizons #CRISPR #Genomics #Partnership

AZ and Cancer Research Horizons extend genomics partnership

Cancer Research Horizons and AstraZeneca have signed a five-year renewal of the Functional Genomics Centre, a facility dedicated to advancing drug discovery with genome-altering technologies such as CRISPR. The Functional Genomics Centre was established in 2019 to explore the function and interaction of genes and proteins… Read More

#News

Kidneys
#AstraZeneca #Clinical trials #Kidney disease #Precision medicine #RNA

AstraZeneca comment on precision medicine for kidney disease 

Regina Fritsche Danielson, Senior Vice President and Global Head, Research and Early Development, CVRM, AstraZeneca, shares insight with DDW’s Megan Thomas on the first precision medicine to treat APOL1-mediated kidney disease (AKMD). MT: Can you provide an overview of the key findings from the study on APOL1-mediated kidney disease (AKMD)? … Read More

#Exclusive Content

Endometrial biopsy
#AstraZeneca #European Commission #Immunotherapy #Oncology #PARP inhibitors #Phase III trial

Lynparza and Imfinzi combination approved in the EU for endometrial cancer

AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient (pMMR) disease. Imfinzi plus… Read More

#News #Regulatory #Trending News

Heart
#AstraZeneca #Clinical trials #Drug development #Drug discovery #Heart failure

Early diagnosis and intervention in heart failure

Heart failure is a collection of different diseases, which can be hard to define and treat through routine clinical practice. Heart failure affects 64 million people globally and approximately half of patients with heart failure die within five years of diagnosis. Real-world data presented at the European Society of Cardiology’s… Read More

#Exclusive Content

Scotland
#AstraZeneca #Kidney disease #NHS Scotland #Partnership #Scotland #University of Dundee #University of Glasgow

Scottish partnership to boost kidney disease research

A new partnership between NHS Scotland, AstraZeneca and the Universities of Dundee and Glasgow hopes to accelerate research into treating chronic kidney disease. The partners will work together on new medicines to slow the progression of chronic kidney disease, reducing the risk that patients might need… Read More

#News

Cancer cell
#AstraZeneca #Breast cancer #EU #Gene mutation #MHRA #Oncology

Capivasertib approved for advanced breast cancer in the UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AstraZeneca’s capivasertib (Truqap) for patients with advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It is approved in cancers that have one or more abnormal PIK3CA, AKT1, or PTEN gene, and does… Read More

#News #Regulatory

siRNA
#Aptamer Group #Aptamers #AstraZeneca #Collaboration #Gene therapy #siRNA

AstraZeneca and Aptamer test liver delivery vehicles with siRNA

Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will explore the potential of the… Read More

#Business & Investment #News

Human heart
#AI #AstraZeneca #BenevolentAI #Collaboration #Drug discovery #Heart failure #Target identification

AI collaboration shows success for novel heart failure target  

AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI.  This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended… Read More

#News

Antibody drug conjugate
#Accelerated assessment #Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Oncology #Solid tumours

First tumour agnostic HER2 directed ADC gets US approval

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. Enhertu has been granted accelerated approval to treat patients who have received prior systemic treatment and have no satisfactory alternative… Read More

#News #Regulatory

Handshake jigsaw puzzle
#AstraZeneca #Clinical trials #MSD #Prostate cancer #Scottish Medicines Consortium

Therapy for advanced prostate cancer approved in Scotland 

The Scottish Medicines Consortium (SMC) has accepted AstraZeneca and MSD’s Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone for adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated, regardless of biomarker status1. Prostate cancer is the most common… Read More

#Cancer Research #News #Regulatory

Non-small cell lung cancer
#AstraZeneca #FDA #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Combination therapy reduced risk of lung cancer progression by 38%

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). It is approved in combination with platinum-based chemotherapy for patients with la/mNSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. Efficacy… Read More

#News #Regulatory

2024 predictions, road forward
#2024 predictions #AstraZeneca #BioSenic #Cancer #Drug discovery #Mosaic Therapeutics #Oncology #OrganaBio #Phesi #Therapeutics

2024 predictions: Experts weigh in on cancer research

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on what to expect from cancer research and immunotherapies. Greg Rossi, Senior Vice… Read More

#Cancer Research #Exclusive Content #Opinion #Trends & Analysis

FDA approval
#AstraZeneca #FDA #hATTR amyloidosis #Ionis #Phase III trial

Wainua approval marks important milestone in amyloidosis treatment

AstraZeneca and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (hATTR-PN or ATTRv-PN). The approval by the US Food and Drug Administration (FDA) was based on the positive 35-week interim analysis from the NEURO-TTRansform Phase III trial. Read More

#News #Regulatory

Biliary tract
#AstraZeneca #Cancer research #National Institute for Health and Care Excellence (NICE) #NHS #Regulatory

Combination therapy recommended for NHS use for biliary tract cancer 

AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) has recommended Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) for NHS use in England and Wales for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1… Read More

#Covid-19 #News

#AstraZeneca #Business #Pfizer #Quarterly review #Regulatory #Sanofi

Drug discovery quarterly review: Second quarter 2023  

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. Business updates   Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational… Read More

#Business & Investment #Exclusive Content #Regulatory

Heart monitor
#AstraZeneca #China #Heart failure #Phase III trial #Regulatory

Forxiga use extended to more heart failure patients in China

AstraZeneca’s Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF. The drug was previously approved in China but was limited to HF patients with reduced ejection fraction (HFrEF). The approval… Read More

#News #Regulatory